News
ASMB
1.070
-8.55%
-0.100
Assembly Biosciences Files $150 Million Mixed Shelf
Assembly Biosciences Files $150 Million Mixed Shelf
MT Newswires · 15h ago
Assembly Biosciences (ASMB) Gets a Buy from Mizuho Securities
TipRanks · 21h ago
BRIEF-Assembly Biosciences Files For Mixed Shelf Of Up To $150 Mln - SEC Filing
Reuters · 1d ago
Assembly Biosciences GAAP EPS of -$1.92 in-line
Seeking Alpha · 1d ago
BRIEF-Assembly Biosciences Posts FY Loss Per Share Of $1.92
Reuters · 1d ago
BRIEF-Assembly Biosciences Nominates First Herpesvirus Development Candidate Abi-5366
Reuters · 02/15 13:51
Assembly Biosciences Has Selected Developing ABI-5366 (5366) To Progress To IND-enabling Studies For Its Long-acting Herpes Simplex Virus Type 2 (HSV-2) Helicase Inhibitor Program
Benzinga · 02/15 13:25
Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB) and Evolus (EOLS)
TipRanks · 01/30 09:20
H.C. Wainwright Keeps Their Hold Rating on Assembly Biosciences (ASMB)
Tip Ranks · 12/29/2022 11:25
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs
Benzinga · 12/19/2022 20:19
Assembly Biosciences Announces Interim Results From Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 And ABI-4334
Benzinga · 12/19/2022 13:10
BRIEF-Assembly Biosciences Announces Promising Interim Results From Two Clinical Trials Evaluating Next-Generation Core Inhibitor Candidates
Reuters · 12/19/2022 13:06
Assembly Biosciences Reports 'Promising' Interim Results of Early Trials in Hepatitis B; Shares Rise
Assembly Biosciences Reports 'Promising' Interim Results of Early Trials in Hepatitis B; Shares Rise
MT Newswires · 12/19/2022 11:24
Mizuho Maintains Buy on Assembly Biosciences, Lowers Price Target to $3
Benzinga · 11/16/2022 13:29
--Mizuho Cuts Price Target on Assembly Biosciences to $3 From $14, Keeps Buy Rating
--Mizuho Cuts Price Target on Assembly Biosciences to $3 From $14, Keeps Buy Rating
MT Newswires · 11/15/2022 09:43
Assembly Biosciences Doses First Subject In Phase 1a Clinical Trial To Evaluate Safety, Tolerability And Pharmacokinetic Profile Of Investigational Next Generation Core Inhibitor ABI-4334
Benzinga · 11/14/2022 13:14
BRIEF-Assembly Biosciences Reports Third Quarter 2022 Financial Results
Reuters · 11/08/2022 23:26
Assembly Biosciences Q3 EPS $(0.48) Down From $(0.41) YoY
Benzinga · 11/08/2022 22:30
Assembly Biosciences GAAP EPS of -$0.48 beats by $0.06
Seekingalpha · 11/08/2022 22:04
More
Webull provides a variety of real-time ASMB stock news. You can receive the latest news about Assembly Bioscie through multiple platforms. This information may help you make smarter investment decisions.
About ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of therapeutics targeting hepatitis B virus (HBV) and other viral diseases. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H3733, and ABI-4334. Vebicorvir (VBR) is its lead core inhibitor product candidate, which is licensed from Indiana University. VBR is developed for the treatment of the treatment of patients with chronic HBV infection. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company is conducting Phase I study of 3733. The Company’s research and development programs pursue multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.